Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Harrow Health, Inc. HROW
$20.32
-$5.07 (-24.94%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
812691560.00000000
-
week52high
28.25
-
week52low
5.40
-
Revenue
88595000
-
P/E TTM
-51
-
Beta
0.17335600
-
EPS
-0.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 20 мая 2022 г. |
| Ladenburg Thalmann | Buy | 02 июл 2021 г. | |
| B. Riley FBR | Buy | Buy | 07 апр 2020 г. |
| B. Riley FBR | Buy | Buy | 16 мар 2020 г. |
| Lake Street | Buy | Buy | 10 дек 2018 г. |
| B. Riley Securities | Buy | Buy | 07 апр 2020 г. |
| B. Riley Securities | Buy | Buy | 16 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BAUM MARK L | D | 0 | 88000 | 02 янв 2023 г. |
| BAUM MARK L | D | 1484962 | 35179 | 02 янв 2023 г. |
| BAUM MARK L | A | 1520141 | 88000 | 02 янв 2023 г. |
| BOLL ANDREW R. | D | 0 | 23000 | 02 янв 2023 г. |
| BOLL ANDREW R. | D | 268461 | 9602 | 02 янв 2023 г. |
| BOLL ANDREW R. | A | 278063 | 23000 | 02 янв 2023 г. |
| BOLL ANDREW R. | A | 255063 | 2500 | 22 дек 2022 г. |
| BAUM MARK L | A | 1432141 | 25000 | 22 дек 2022 г. |
| Van Horn R. Lawrence | A | 1860 | 1860 | 22 дек 2022 г. |
| Makary Martin A. | A | 25000 | 25000 | 21 дек 2022 г. |
Новостная лента
Harrow Health, Inc. (HROW) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 21:43
Harrow Health, Inc. (NASDAQ:HROW ) Q1 2023 Earnings Conference Call May 11, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Securities Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call.
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Harrow Health (HROW) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.03 per share a year ago.
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
Zacks Investment Research
08 мая 2023 г. в 13:43
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
5 Stocks With Recent Price Strength That Still Have Upside
Zacks Investment Research
03 мая 2023 г. в 08:22
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
Here's Why Momentum in Harrow (HROW) Should Keep going
Zacks Investment Research
01 мая 2023 г. в 09:55
Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.